Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.35 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL257777 | 0.78 | MRGPRX4 (0.57) | MRGPRX4FFAR4FFAR1PPARA | |
| SCHEMBL26434787 | 0.77 | MRGPRX4 (0.58) | MRGPRX4FFAR4MAOBALDH1A1 | |
| SCHEMBL15588794 | 0.74 | MRGPRX4 (0.56) | MRGPRX4MAPK14FFAR4FFAR1MAOB | |
| SCHEMBL12993001 | 0.72 | LOXL2 (0.38) | MAOBLOXL2CSNK2A1 | |
| SCHEMBL16210864 | 0.72 | MRGPRX4 (0.53) | MRGPRX4MAPK14MAOBALDH1A1 | |
| SCHEMBL171841 | 0.71 | MRGPRX4 (0.68) | MRGPRX4FFAR4MAOB | |
| SCHEMBL26698908 | 0.71 | MRGPRX4 (0.56) | MRGPRX4FFAR4FFAR1MAOB | |
| SCHEMBL3126227 | 0.71 | KDM1A (0.51) | FFAR1ROCK2AKT1ROCK1RPS6KA1 | |
| SCHEMBL14392653 | 0.71 | MRGPRX4 (0.44) | MRGPRX4ALDH1A1 | |
| SCHEMBL30931597 | 0.70 | LOXL2 (0.58) | LOXL2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4085059-B1 | HETEROARYL COMPOUNDS AS INHIBITORS OF PROGRAMMED NECROSIS PATHWAY, COMPOSITION AND METHOD USING THE SAME | ACCRO BIOSCIENCE HK LTD (HK) | 2024-03-20 | — | — | EP | disclosed |
| US-20230121233-A1 | Heteroaryl compounds as inhibitors of programmed necrosis pathway, composition and method using the same | ACCRO BIOSCIENCE (HK) LIMITED (HK) | 2023-04-20 | — | — | US | disclosed |
| WO-2021138694-A1 | HETEROARYL COMPOUNDS AS INHIBITORS OF PROGRAMMED NECROSIS PATHWAY, COMPOSITION AND METHOD USING THE SAME | ACCRO BIOSCIENCE INC. (KY) | 2021-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230121233-A1 | Heteroaryl compounds as inhibitors of programmed necrosis pathway, composition and method using the same | BAX, PDCD1, PDCD4 | MRGPRX4 3351/4885MAPK14 844/4885FFAR4 2327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.